Emerald Advisers LLC Buys 41,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Emerald Advisers LLC lifted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 416,866 shares of the biotechnology company's stock after purchasing an additional 41,000 shares during the quarter. Blueprint Medicines accounts for 1.4% of Emerald Advisers LLC's investment portfolio, making the stock its 16th largest holding. Emerald Advisers LLC owned 0.66% of Blueprint Medicines worth $36,359,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Quarry LP acquired a new position in Blueprint Medicines during the third quarter worth $32,000. R Squared Ltd bought a new stake in shares of Blueprint Medicines during the fourth quarter worth about $51,000. Asset Management One Co. Ltd. acquired a new stake in shares of Blueprint Medicines in the 4th quarter worth about $88,000. Van ECK Associates Corp lifted its position in Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after acquiring an additional 363 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Blueprint Medicines during the 3rd quarter valued at about $108,000.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Scotiabank initiated coverage on Blueprint Medicines in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 price objective for the company. Jefferies Financial Group initiated coverage on Blueprint Medicines in a research report on Monday, March 17th. They issued a "buy" rating and a $135.00 price target for the company. Wedbush reaffirmed an "outperform" rating and set a $128.00 price objective on shares of Blueprint Medicines in a report on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Finally, Piper Sandler raised their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Blueprint Medicines currently has an average rating of "Moderate Buy" and an average target price of $124.95.

Remove Ads

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC traded down $0.99 during trading on Thursday, hitting $89.73. 651,991 shares of the company were exchanged, compared to its average volume of 712,083. Blueprint Medicines Co. has a 52-week low of $80.68 and a 52-week high of $121.90. The stock has a 50 day moving average of $98.55 and a 200 day moving average of $93.92. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market cap of $5.73 billion, a PE ratio of -83.08 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,250 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the sale, the insider now directly owns 14,967 shares in the company, valued at $1,496,700. This represents a 13.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares of the company's stock, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,608 shares of company stock valued at $3,319,587. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.